Tadesse, S.Zhu, G.Mekonnen, L.B.Lenjisa, J.L.Yu, M.Brown, M.P.Wang, S.2020-08-192020-08-192017Future Medicinal Chemistry, 2017; 9(13):1495-15061756-89191756-8927http://hdl.handle.net/2440/127114Inhibitors of CDK4/6 have emerged as a powerful class of therapeutics for treatment of several malignancies. We herein describe the identification of a new series of molecules that demonstrated excellent selectivity for CDK4/6 over CDKs1, 7 and 9.Medicinal chemistry optimization led to the discovery of 58 and 69 that inhibited CDK4 and CDK4/6, respectively, with high potency and selectivity, and 58 and 69 exhibited potent antiproliferative activities in a panel of human cancer cell lines including leukemia, and cancers of the breast, colon, ovary, pancreas and prostate.Compounds 58 and 69 caused remarkable growth inhibition of melanoma cells, particularly the cells harboring multiple BRAF and NRAS mutations, via a CDK4/6-targeted mechanism of action. [Formula: see text].en© 2017 Future Science Ltd.Cell Line, TumorHumansAminesPyridinesPyrimidinesThiazolesGTP PhosphohydrolasesProto-Oncogene Proteins B-rafRetinoblastoma ProteinMembrane ProteinsProtein Kinase InhibitorsCell ProliferationBinding SitesProtein Structure, TertiaryProtein BindingStructure-Activity RelationshipPhosphorylationCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6G1 Phase Cell Cycle CheckpointsJournal article003008415810.4155/fmc-2017-00760004112324000062-s2.0-85029705736367168Brown, M.P. [0000-0002-5796-1932] [0000-0002-6678-1407]